Watchmaker to Unveil New Technologies Addressing NGS Workflow Bottlenecks and Sequencing Accuracy Challenges at ESHG 2026
9.6.2026 14:00:00 CEST | Business Wire | Press release
New technologies advance scalable library normalization for high-throughput genomics labs and improved amplification accuracy for oncology-focused sequencing workflows where data quality is critical
Watchmaker Genomics, a leader in high-performance NGS workflow solutions, today announced it will unveil two new technologies at the European Society of Human Genetics (ESHG) 2026 conference, designed to address persistent bottlenecks in sequencing workflow scalability and amplification accuracy.
The launches include the EquiPlex™ Normalization Kit, which simplifies library normalization using a novel Cas9-based approach, and Equinox® Prime Library Amplification Master Mix, engineered to improve indel accuracy in repetitive genomic regions while delivering superior amplification performance across sequencing applications.
Built on Watchmaker’s expertise in protein engineering and integrated workflow design, the technologies reflect the company’s continued focus on solving real-world sequencing challenges that impact operational efficiency, scalability, and downstream data quality.
“Sequencing workflows continue to grow in scale and complexity, but many of the core bottlenecks researchers face today remain fundamentally unchanged,” said Trey Foskett, CEO of Watchmaker. “These launches reflect our focus on engineering technologies that not only improve data quality but also simplify workflows and enable researchers to operate more efficiently at scale.”
EquiPlex™ Normalization Kit Simplifies Library Pooling at Scale
EquiPlex introduces a novel approach to library normalization by repurposing CRISPR-Cas9 technology as a stoichiometric molecular binding tool rather than a cutting enzyme. The technology captures a fixed number of molecules from each library, regardless of the starting concentration, enabling rapid, automated normalization across a broad range of applications and sample types.
The workflow eliminates the need for library concentration quality control (QC), dilution calculations, and variable-volume pipetting steps that are difficult to automate, error-prone, and commonly contribute to pooling variability and sequencing imbalance. Compatible with existing RNA-seq, DNA-seq, and methylation sequencing workflows, EquiPlex is designed to streamline sequencing operations and improve pooling consistency without requiring researchers to redesign established library preparation processes.
“Normalization of libraries prior to pooling has always been an annoyance, especially when working at scale,” noted Graham Wiley, PhD, Director of Clinical Genomics Center at Oklahoma Medical Research Foundation. “Our previous pipelines would often still have an amount of variability that left us needing to perform additional sequencing to reach coverage goals. With Equiplex we've finally found the level of pooling consistency we were searching for.”
Watchmaker is further adapting this CRISPR-enabled normalization strategy as a core component of a novel PCR-free whole genome sequencing solution, designed to streamline fragmentation, normalization, and library construction for labs that require robust, reproducible, high-quality WGS data at scale.
Equinox Prime Improves Amplification Accuracy in Challenging Genomic Regions
Watchmaker will also debut Equinox Prime Library Amplification Master Mix, a next-generation amplification solution engineered to reduce polymerase slippage in homopolymer and repetitive genomic regions prone to indel artifacts.
The technology was designed to improve variant calling accuracy in applications where indel precision is critical, including somatic oncology workflows such as microsatellite instability (MSI) profiling, while also delivering broad performance benefits across whole genome sequencing (WGS), whole exome sequencing (WES), and other sequencing applications.
Beyond improved indel accuracy, Equinox Prime delivers low error rates, high library yields, and uniform GC coverage to support demanding sequencing workflows where amplification performance directly impacts downstream sequencing quality.
“Researchers have historically had to make trade-offs in library amplification performance, balancing yield and coverage uniformity against sequencing accuracy depending on the application,” said Brian Kudlow, CSO of Watchmaker. “Equinox Prime was engineered to eliminate those compromises by delivering improved indel accuracy in repetitive regions alongside low error rates, high yields, and even GC coverage in a single solution.”
Debuting at ESHG 2026
Watchmaker will showcase these advances at ESHG in Gothenburg, Sweden in its featured workshop From Multiomics to Multiplexing: Integrated Advances in DNA, RNA, and Epigenomic Profiling on Monday, June 15th.
The workshop will highlight new approaches for improving sequencing quality, simplifying workflows, and enabling scalable genomics across DNA, RNA, and epigenomic applications, including the debut of EquiPlex and Equinox Prime.
About Watchmaker Genomics
Watchmaker Genomics is a life sciences company focused on developing high-performance tools that empower genomic research and clinical applications. Leveraging expertise in protein engineering and next-generation sequencing, Watchmaker delivers precision reagents and platforms that enable superior accuracy, efficiency, and cost-effectiveness in molecular analysis. The company is dedicated to advancing breakthrough technologies to support innovations in cancer detection, epigenetics, and liquid biopsy applications.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260609044273/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Polymorph of Indomethacin Discovered9.6.2026 17:00:00 CEST | Press release
- Joint Research Involving Rigaku Published in Crystal Growth & Design - Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; “Rigaku”), announced that the results of a joint research project conducted with Shionogi & Co., Ltd., JEOL Ltd., and Meiji Pharmaceutical University have been published in Crystal Growth & Design, a world-renowned international journal in the field of crystallography. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609347405/en/ Cover of the June 2026 issue of Crystal Growth & Design, featuring this research. This research uncovered a previously unknown polymorph (κ-form) of indomethacin, a widely used pain relief and anti-inflammatory drug. The research team also conducted structural analysis and characterization of the newly identified crystal form. Although indomethacin has
SLB Collaborates with Qualcomm on Edge AI Solutions for Energy Operations9.6.2026 16:28:00 CEST | Press release
Collaboration combines edge computing and energy workflows to support real-time operational decision-making Global energy technology company SLB (NYSE: SLB) today announced a memorandum of understanding with Qualcomm Technologies, Inc. to enable edge AI solutions for the energy industry, supporting real-time operational decision-making across wells, facilities and production systems. The collaboration combines Qualcomm Technologies’ low-power edge computing and AI processing capabilities, with SLB’s Agora™ edge AI and IoT solutions developed for remote and operationally complex environments. “Together, SLB and Qualcomm Technologies aim to help operators apply AI more effectively across energy infrastructure,” said Rakesh Jaggi, president, Digital, SLB. “Many energy operations rely on real-time decision-making in remote environments where connectivity and responsiveness directly affect performance. AI systems designed around the realities of energy operations can help support more consi
RevBits and Stony Brook University’s Ethos Lab Establish a Collaborative Partnership to Further the Field of Cyber Security Education and Application9.6.2026 16:15:00 CEST | Press release
Through the partnership, RevBits will provide its full suite of cybersecurity solutions to Stony Brook University’s Ethos Lab, to deliver the capability to advance student education and equip them with the knowledge needed to face modern cyber threats in a realistic, contained environment. Stony Brook University’s (SBU) Ethos Lab, in the College of Engineering and Applied Sciences Department of Computer Science, recently announced a collaborative partnership with RevBits, LLC. Through the partnership, SBU’s Ethos Lab will utilize the RevBits solutions suite to build computer science labs and a cybersecurity-focused curriculum, reinforcing lessons from the classroom. The platform simulates environments containing five major threat landscapes, including Endpoint Security, Privileged Access Management, Email Security, Zero Trust Network and Deception Technology. SBU’s Department of Computer Science was recently designated as a National Center of Academic Excellence in Cybersecurity Resear
Marie® by Leo Cancer Care Makes History at Stanford Medicine — World First in Compact Upright Proton Therapy9.6.2026 15:22:00 CEST | Press release
The first patient treated was a child. The milestone marks the moment upright proton therapy moves from innovation to adoption — and reflects exactly what Leo Cancer Care built Marie® to achieve Following the landmark first treatment at Stanford Medicine Cancer Center Care June 4, Leo Cancer Care today announces the role of its Marie® upright patient positioning and imaging platform in enabling the world's first compact upright proton therapy patient treatment. Delivered using the Mevion S250-FIT™ Proton Therapy System and powered by RayStation from RaySearch, the milestone is the culmination of a decade of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609870736/en/ The treatment room at Stanford Medicine Cancer Center, Palo Alto, California, housing the Marie® upright patient positioning platform by Leo Cancer Care (center foreground) integrated with the Mevion S250-FIT™ Proton Therapy System. The circular
Volante Technologies launches “Vol360i” Agentic AI at the core of payments, setting a new global standard for intelligence in banking9.6.2026 15:00:00 CEST | Press release
Agents deliver configurable, confidence-based automation and predictability to financial institutions through exception handling, routing, and SLA monitoring Volante Technologies, the global leader in Payments as a Service (PaaS), today announced that its Payments Platform and PaaS operations are now powered by its “Vol360i” Agentic AI. The core upgrade unlocks autonomous and semi-autonomous collaboration to reduce manual intervention, significantly increasing straight-through processing (STP) rates to over 95%, accelerating exception resolution, and proactively managing SLA performance. Vol360i is immediately available to Volante banking and financial institution clients, with four main operating principles guiding Volante’s agentic framework to deliver a frictionless payments experience: Prevent Agents: Eliminate failures before they occur, boosting reliability and reducing customer-impacting errors. Repair Agents: Self-healing AI fixes problems in real time, allowing operators to fo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom